e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
The immunology of allergic airway disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium
Irene Heijink (Groningen, Netherlands), Irene Heijink, Marnix Jonker, Dirkje Postma, Maarten Van den Berge
Source:
International Congress 2015 – The immunology of allergic airway disease
Session:
The immunology of allergic airway disease
Session type:
Thematic Poster Session
Number:
2558
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Irene Heijink (Groningen, Netherlands), Irene Heijink, Marnix Jonker, Dirkje Postma, Maarten Van den Berge. Differential effects of budesonide and fluticasone propionate on immune defense genes in human bronchial epithelium. Eur Respir J 2015; 46: Suppl. 59, 2558
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Differential effects of budesonide and fluticasone propionate on bacterial recognition receptors in COPD macrophages
Source: International Congress 2016 – Airway response to infection
Year: 2016
Differential effects of budesonide and fluticasone propionate on expression of lactotransferrin in airway epithelium
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Differential effects of budesonide and fluticasone propionate on bronchial epithelial barrier function
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Budesonide and fluticasone propionate exertdifferential effects on human bronchial epithelial cells exposed to streptococcus pneumoniae and viral mimetic
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Differential effect of fluticasone on Poly(I:C) induced TSLP secretion by bronchial epithelial cells from asthmatic children
Source: International Congress 2016 – Mechanisms of disease
Year: 2016
Fluticasone propionate reduces bacterial airway epithelial invasion
Source: Eur Respir J 2008; 32: 1283-1288
Year: 2008
Initial interaction of fluticasone propionate with ciliated respiratory epithelium
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Comparison of fluticasone propionate and budesonide on phagocytosis of common respiratory pathogens in COPD patients
Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD
Year: 2011
Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 317s
Year: 2006
Multiple synergistic effects of fluticasone propionate and salmeterol on T-cell activation in bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 250s
Year: 2004
Nasal fibroblast functions involved in airway inflammation and remodelling are downregulated by fluticasone propionate (FP)
Source: Eur Respir J 2001; 18: Suppl. 33, 147s
Year: 2001
Tiotropium and fluticasone inhibit rhinovirus-induced mucin production via multiple mechanisms in differentiated airway epithelial cells
Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity
Year: 2020
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD
Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD
Year: 2005
Effects of mometasone and formoterol on the innate immunity of human gingival epithelial cells
Source: International Congress 2017 – Infection and exacerbation science
Year: 2017
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma
Source: Eur Respir J 2002; 20: 66-72
Year: 2002
Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Anticholinergic treatment does not affect toll-like receptor 3-induced antiviral immune response in COPD bronchial epithelial cells
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function
Source: Eur Respir J 2008; 32: 989-996
Year: 2008
Anti-inflammatory effect of the combination of a long acting β2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following
staphylococcus aureus
virulence factors challenge
Source: Eur Respir J 2006; 28: Suppl. 50, 104s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept